Breaking
National Archives Expands Its Most Hallowed Chamber With Two Historic Documents Call of Duty's Dave Chappelle Bundle Sparks Backlash Over Tonal Shift Federal Judge Orders Penn to Provide Data on Jewish Employees for Discrimination Probe Each serving of ultra-processed food raises heart disease risk, major study finds GOP Strategy to Bypass Congress on Homeland Security Funding Raises Power Concerns National Archives Expands Its Most Hallowed Chamber With Two Historic Documents Call of Duty's Dave Chappelle Bundle Sparks Backlash Over Tonal Shift Federal Judge Orders Penn to Provide Data on Jewish Employees for Discrimination Probe Each serving of ultra-processed food raises heart disease risk, major study finds GOP Strategy to Bypass Congress on Homeland Security Funding Raises Power Concerns
Health

Oral Cholesterol Drug Shows Promise Rivaling Injectable Treatments

Jessica Williams 0 comments 7 min read
Oral Cholesterol Drug Shows Promise Rivaling Injectable Treatments

A newly tested oral medication has demonstrated the ability to slash LDL cholesterol levels by approximately 60%, matching the effectiveness of existing injectable therapies in a major clinical trial.

The drug, enlicitide, addresses a significant gap in cholesterol management. Current injectable treatments work well but require regular infusions or injections, a barrier that discourages many patients from pursuing the therapy despite its benefits. By delivering similar results in pill form, the medication could remove a major obstacle to treatment compliance.

The trial results highlight a persistent public health problem: a substantial portion of patients fail to reach target cholesterol levels even while taking statins, the standard first-line medication. This treatment gap leaves millions at elevated risk for heart disease and stroke.

Researchers involved in the study emphasize that having more effective options—particularly oral formulations—is crucial for helping patients manage cholesterol more aggressively. The finding suggests enlicitide could fill an important role for people whose cholesterol remains dangerously high despite existing interventions.

The 60% reduction observed in the trial places the oral medication in the same performance tier as PCSK9 inhibitors and other advanced injectable cholesterol treatments that have become standard options for high-risk patients over the past decade. However, ease of administration could give enlicitide a significant advantage in real-world settings where adherence to medication regimens determines long-term health outcomes.

The trial results are expected to inform regulatory decisions about the drug's approval pathway. If cleared for use, enlicitide would expand the arsenal available to cardiologists treating patients with stubborn or familial high cholesterol.

Comments